NEWS ABOUT DARZALEX®

PATIENT SITE

Discover

More Possibilities

A new option for patients with multiple myeloma: DARZALEX® can now be used in combination with Revlimid® (lenalidomide) and dexamethasone or Velcade® (bortezomib) and dexamethasone in patients who have received at least one prior medicine.

How does DARZALEX® work?
  • DARZALEX® is not chemotherapy. DARZALEX® is a monoclonal antibody that works with your immune system. Monoclonal antibodies work by attaching themselves to multiple myeloma cells in your body and directly killing them, and/or signaling your immune system to destroy them
  • DARZALEX® finds and attaches to a protein called CD38, which is present on the surface of cells, including high numbers on myeloma cells
RESULTS SEEN IN CLINICAL TRIALS
  • The main goal of the study was to measure the length of time patients live without their multiple myeloma getting worse or their passing away from any cause
    • Another goal was to measure response rate, which is the percentage of patients who responded to treatment. Talk to your doctor about how response is measured
  • The majority of patients responded to the following DARZALEX® combination treatments:
    • ​DARZALEX® was studied in combination with Revlimid® and dexamethasone (Rd) vs Rd alone in 569 patients who had received a minimum of 1 prior treatment
      • 9 out of 10 patients responded to DARZALEX® + Rd vs 7 out of 10 with Rd alone
    • DARZALEX® was studied in combination with Velcade® and dexamethasone (Vd) vs Vd alone in 498 patients who had received a minimum of 1 prior treatment
      • Almost 8 out of 10 patients responded to DARZALEX® + Vd vs almost 6 out of 10 with Vd alone
  • DARZALEX® combination treatments reduced patients’ risk of their disease getting worse or their passing away from any cause by more than 60%

Sign up to receive updates and more information.

Click here if you are a healthcare professional.

Revlimid® is a registered trademark of Celgene Corporation.
Velcade® is a registered trademark of Millennium Pharmaceuticals, Inc.

Home

When your multiple myeloma relapses again and again,

My Reason toDiscoverWhat’s Possible

DARZALEX® (daratumumab) is a prescription medicine used to treat a type of cancer called multiple myeloma in people who:

  • Have received at least 3 prior medicines to treat multiple myeloma, including a proteasome inhibitor (PI) and an immunomodulatory agent, or
  • Did not respond to a PI and an immunomodulatory agent

It is not known if DARZALEX® is safe and effective in children.

DARZALEX® is approved based on response. Clinical trials are still ongoing.

DARZALEX®—a Monoclonal Antibody

I’m interested in learning more about what DARZALEX® is and how it works.

I've been prescribed DARZALEX® and I'd like to see how my treatment schedule might look over the next few months.
About DARZALEX®

How does DARZALEX® work?

DARZALEX® is a monoclonal antibody that works with your immune system. Ask your doctor if DARZALEX® is right for you.  

DARZALEX® (daratumumab) Mechanisms of Action

DARZALEX® finds and attaches to a protein called CD38, which is present on the surface of cells, including high numbers on myeloma cells.

Once DARZALEX® attaches to the CD38 protein, it works in many ways, by helping your immune system find and kill myeloma cells and/or by killing the myeloma cells on its own.

DARZALEX® Treatment

My Treatment Schedule

Select the date on which you expect to receive your first DARZALEX® treatment. Once a date is selected, recommended subsequent treatment dates will automatically populate within the calendar.*

Tap a date below to begin.
My Treatment Schedule

Select the date on which you expect to receive your first DARZALEX® treatment. Once a date is selected, recommended subsequent treatment dates will automatically populate within the calendar.*

Tap a date below to begin.
Infusion Dates
Weeks 1-8
Weekly Infusions
Weeks 1-8 (weekly infusions)
Weeks 9-24
Infusions Every 2 Weeks
Weeks 9-24 (infusions every 2 weeks)
Weeks 25+
Infusions Every 4 Weeks
Weeks 25+ (infusions every 4 weeks)

* Please note that dates provided are recommendations for infusion visits only. Your doctor is likely to schedule additional follow-up/care visits and may alter the dates for your infusions depending on your availability and office availability.

Infusion centers may not offer weekend and/or holiday appointments.

Please contact the center to confirm hours of operation.

You have chosen a new start date.

Would you like to clear your old dosing schedule and create a new one?

Please select the date you plan to receive your first DARZALEX® dose.

Want a PDF of this treatment schedule?

Preparing for Treatment

Learn what you can expect before treatment with DARZALEX®.

Explore More
Patient and Caregiver Stories

Learn from patients on DARZALEX® and their caregivers about their experiences.

Infusion Tips

Learn about some useful tips to help you prepare for your infusion and feel comfortable during your appointments.

Janssen CarePath

Janssen CarePath provides ongoing support, education, and resources during your treatment with DARZALEX®.

Support at every step

Would you like to receive e-mails and other communications from Janssen CarePath that are designed to support you during your treatment journey?